Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 6

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

Authors Behzad Molavi, Negah Rassouli, Suveer Bagwe, Neda Rasouli

Published Date January 2007 Volume 2007:3(6) Pages 967—973

DOI http://dx.doi.org/

Published 15 January 2007

Behzad Molavi1, Negah Rassouli2, Suveer Bagwe1, Neda Rasouli2

Central Arkansas Veterans Healthcare System and University of Arkansas for Medical sciences, 1Division of cardiology and 2Division of Endocrinology, College of Medicine, Little Rock, Arkansas, USA

Abstract: The rising incidence of obesity and insulin resistance to epidemic proportions has closely paralleled the surge in the prevalence of diabetes and outpaced therapeutic advances in diabetes prevention and treatment. Current evidence points to obesity induced oxidative stress and chronic inflammation as the common denominators in the evolution of insulin resistance and diabetes. Of all the hypoglycemic agents in the pharmacological arsenal against diabetes, thiazolidinediones, in particular pioglitazone, as well as metformin appear to have additional effects in ameliorating oxidative stress and inflammation; rendering them attractive tools for prevention of insulin resistance and diabetes. In addition to their hypoglycemic and lipid modifying properties, pioglitazone and metformin have been shown to exert anti-oxidative and anti-inflammatory effects in vascular beds, potentially slowing the accelerated atherosclerosis in diabetes, which is the major cause of morbidity and mortality in the affected population. The combination of pioglitazone and metformin would thus appear to be an effective pharmacological intervention in prevention and treatment of diabetes. Finally, this review will address the currently available evidence on diabetic cardiomyopathy and the potential role of combination therapy with pioglitazone and metformin.

Keywords: insulin resistance, oxidative stress, inflammation, pioglitazone, metformin, atherosclerosis, diabetic cardiomyopathy

Download Article [PDF] 

Readers of this article also read:

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum]

Soosay Raj TA, Smith AM, Moore AS

International Journal of Nanomedicine 2013, 8:4705-4706

Published Date: 5 December 2013

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia

Soosay Raj TA, Smith AM, Moore AS

International Journal of Nanomedicine 2013, 8:4361-4369

Published Date: 6 November 2013

Effects of Arthro-7® in relieving symptoms of osteoarthritis with mild to moderate arthralgia [Corrigendum]

Xie Q, Zhou T, Yen L, Shariff M, Nguyen T, Kami K, Gu P, Liang L, Rao J, Shi R

Nutrition and Dietary Supplements 2013, 5:7-8

Published Date: 16 May 2013

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2013, 7:129-130

Published Date: 16 January 2013

Erratum

Todd Levine

Drug Design, Development and Therapy 2012, 6:163-164

Published Date: 21 June 2012

Further data on the association between Helicobacter pylori infection and primary open-angle glaucoma

Zavos C, Kountouras J

Clinical Ophthalmology 2012, 6:243-245

Published Date: 10 February 2012

Corrigendum

Escobar-Chávez JJ, Domínguez-Delgado CL, Rodríguez-Cruz IM

Drug Design, Development and Therapy 2011, 5:487-488

Published Date: 28 November 2011

Corrigendum

Sudenga SL, Royse KE, Shrestha S

Adolescent Health, Medicine and Therapeutics 2011, 2:95-96

Published Date: 15 September 2011

Erratum

Schuelert N, Russell FA, McDougall JJ

Orthopedic Research and Reviews 2011, 3:9-10

Published Date: 1 March 2011

Transradial approach to lower extremity interventions

Ravikiran Korabathina, Sidharth S Yadav, John T Coppola, et al

Vascular Health and Risk Management 2010, 6:503-509

Published Date: 1 July 2010